Table 4.
Surgery and pathological staging for patients
| Characteristics | Overall (n = 123) |
|---|---|
| Time from NCRT to surgery (weeks), median (IQR) | 6.7 (5.4–8.3) |
| Pathological T stage, n (%) | |
| pT0 | 52 (42.3) |
| pT1 | 15 (12.2) |
| pT2 | 19 (15.4) |
| pT3 | 35 (28.5) |
| pT4a | 2 (1.6) |
| Pathological N stage, n (%) | |
| pN0 | 82 (66.7) |
| pN1 | 24 (19.5) |
| pN2 | 13 (10.6) |
| pN3 | 4 (3.3) |
| Pathological TNM stage, n (%) | |
| pT0N0 | 46 (37.4) |
| I | 14 (11.4) |
| II | 33 (26.8) |
| III | 30 (24.4) |
| Tumor regression grade, n (%) | |
| 0 | 46 (37.4) |
| 1 | 11 (8.9) |
| 2 | 60 (48.8) |
| 3 | 6 (4.9) |
| R0 resection, n (%) | |
| All location | 104 (84.6) |
| Upper | 18 (14.6)a |
| Middle | 48 (39.0)a |
| Lower | 38 (30.9)a |
Abbreviations: NCRT neoadjuvant chemoradiotherapy, IQR interquartile range
aLocation specific R0 resection rate: upper (75.0%), middle (81.7%), lower (94.9%)